USC.edu
Are You a Patient?

Shahab Asgharzadeh, MD

Professor of Pediatrics and Pathology

Image of Shahab Asgharzadeh, MD
Is this your profile? Click to edit
Phone +1 323 361 8643
Email [email protected]
CTSI Profile

Education and Training

  • University of Illinois, Chicago, Illinois — MD — 06/1996 — Medicine
  • Northwestern University, Evanston, Illinois — BS — 06/1992 — Biomedical Engineering

Publications

  • The role of spatial transcriptomics in exploring the tumor microenvironment in neuroblastoma. Biochem Pharmacol. 2026 Sep 15; 254(Pt 2):118474.. View in PubMed
  • A human stem cell model of neuroblastoma identifies four chromosome 17q genes that drive tumor initiation and progression. Cancer Lett. 2026 Aug 26; 660:218781.. View in PubMed
  • hTERT Expression, Regulation, and Prognostic Significance in Pediatric Medulloblastoma. bioRxiv. 2026 May 06.. View in PubMed
  • Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group. Clin Cancer Res. 2026 Jan 06; 32(1):127-134.. View in PubMed
  • Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG. Oncogene. 2025 10; 44(39):3694-3712.. View in PubMed
  • Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. J Exp Med. 2025 Sep 01; 222(9).. View in PubMed
  • Extracellular Matrix Topography Drives Adrenergic to Mesenchymal Transition in Neuroblastoma. Adv Mater. 2025 Sep; 37(37):e2501526.. View in PubMed
  • Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 08; 43(22):2490-2501.. View in PubMed
  • Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum. Pediatr Blood Cancer. 2025 Sep; 72(9):e31831.. View in PubMed
  • CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells. Blood Cancer Discov. 2025 01 08; 6(1):55-72.. View in PubMed

Similar People